Invesco
BOLD

Invesco’s Audentes Therapeutics, Inc BOLD Stock Holding History

Invesco’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-161,137
Closed -$6.38M – 3919
2018
Q3 		$6.38M Buy
161,137
+40,906
+34% +$1.52M ﹤0.01% 2011
2018
Q2 		$4.59M Buy
120,231
+68,989
+135% +$2.56M ﹤0.01% 2188
2018
Q1 		$1.54M Buy
+51,242
New +$1.73M ﹤0.01% 2769

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Invesco's BOLD Position: Q4 2018 in Review

Invesco sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 161,137 shares — an estimated $6.38M sold.

Invesco first reported a position in BOLD in Q1 2018 and held it in 3 quarters. The position peaked at $6.38M in Q3 2018. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • Invesco reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Invesco sold 161,137 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $6.38M.
  • Invesco first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 3 quarters.
  • Invesco's Audentes Therapeutics, Inc position peaked at $6.38M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on Invesco's 13F filing for Q4 2018, filed 14 Feb 2019.